FT516 and IL2 With Enoblituzumab for Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Ovarian Cancer
Related studies linked through entity extraction aliases.
Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory
- Status
- COMPLETED
- Phase
- N/A
Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers
- Status
- COMPLETED
- Phase
- NA
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study
- Status
- UNKNOWN
- Phase
- N/A
Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC)
- Status
- TERMINATED
- Phase
- PHASE1
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
BrUOG 390: Neoadjuvant Treatment With Talazoparib
- Status
- TERMINATED
- Phase
- PHASE1
Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
- Status
- TERMINATED
- Phase
- PHASE1
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
- Status
- UNKNOWN
- Phase
- N/A
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
- Status
- AVAILABLE
- Phase
- N/A